CN119032099A - 纯化产品的方法 - Google Patents

纯化产品的方法 Download PDF

Info

Publication number
CN119032099A
CN119032099A CN202380033420.7A CN202380033420A CN119032099A CN 119032099 A CN119032099 A CN 119032099A CN 202380033420 A CN202380033420 A CN 202380033420A CN 119032099 A CN119032099 A CN 119032099A
Authority
CN
China
Prior art keywords
protein
antibody
affinity chromatography
eluate
buffer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202380033420.7A
Other languages
English (en)
Chinese (zh)
Inventor
安德里亚斯·塞巴斯蒂安·楚尔布里根
卡罗尔·印-阿尔本
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
KO DA Pharmaceutical Co Ltd
Original Assignee
KO DA Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by KO DA Pharmaceutical Co Ltd filed Critical KO DA Pharmaceutical Co Ltd
Publication of CN119032099A publication Critical patent/CN119032099A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/248—IL-6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Treatment Of Liquids With Adsorbents In General (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CN202380033420.7A 2022-02-10 2023-02-09 纯化产品的方法 Pending CN119032099A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263267810P 2022-02-10 2022-02-10
US63/267,810 2022-02-10
PCT/US2023/062322 WO2023154822A2 (en) 2022-02-10 2023-02-09 Methods of purifying a product

Publications (1)

Publication Number Publication Date
CN119032099A true CN119032099A (zh) 2024-11-26

Family

ID=87521638

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202380033420.7A Pending CN119032099A (zh) 2022-02-10 2023-02-09 纯化产品的方法

Country Status (10)

Country Link
US (1) US20230250133A1 (enExample)
EP (1) EP4476237A2 (enExample)
JP (1) JP2025505696A (enExample)
KR (1) KR20240142564A (enExample)
CN (1) CN119032099A (enExample)
AU (1) AU2023217074A1 (enExample)
CA (1) CA3251000A1 (enExample)
IL (1) IL314472A (enExample)
MX (1) MX2024009755A (enExample)
WO (1) WO2023154822A2 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119454939A (zh) * 2024-11-28 2025-02-18 北海康成(苏州)生物制药有限公司 一种欧莫扑拜单抗原液及其制备方法
CN119524125A (zh) * 2024-11-28 2025-02-28 北海康成(苏州)生物制药有限公司 一种欧莫扑拜单抗原液的生产方法及欧莫扑拜单抗原液

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015035342A2 (en) 2013-09-08 2015-03-12 Oligasis Llc Factor viii zwitterionic polymer conjugates
AU2018250695A1 (en) 2017-04-14 2019-11-07 Kodiak Sciences Inc. Complement factor D antagonist antibodies and conjugates thereof
US12071476B2 (en) 2018-03-02 2024-08-27 Kodiak Sciences Inc. IL-6 antibodies and fusion constructs and conjugates thereof
AU2020364071A1 (en) 2019-10-10 2022-05-26 Kodiak Sciences Inc. Methods of treating an eye disorder
WO2025073922A1 (en) * 2023-10-04 2025-04-10 Sartorius Bia Separations D.O.O. Enhanced chromatographic separations of components in a mixture by employing chaotropic elution
WO2025184423A1 (en) * 2024-02-29 2025-09-04 Kodiak Sciences Inc. Cell-surface-targeting-domain-polymer-payload conjugate
US20260092109A1 (en) * 2024-09-06 2026-04-02 Eyebiotech Limited Multivalent fzd4, wnt co-receptor, and vegf receptor molecules and uses thereof
US20260092125A1 (en) * 2024-09-06 2026-04-02 Eyebiotech Limited Multivalent fzd4, wnt co-receptor, and vegf binding molecules and uses thereof
WO2026075981A1 (en) * 2024-10-01 2026-04-09 Regeneron Pharmaceuticals, Inc. Methods of analyzing heterodimeric proteins

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7045314B2 (en) * 2000-04-04 2006-05-16 Baxter International Inc. Method for the production of bacterial toxins
RU2011137030A (ru) * 2009-03-11 2013-04-20 УАЙТ ЭлЭлСи Способы очистки малых модулярных иммунофармацевтических белков
AU2012328880B2 (en) * 2011-10-24 2017-02-23 Halozyme, Inc. Companion diagnostic for anti-hyaluronan agent therapy and methods of use thereof
ES2895752T3 (es) * 2014-01-03 2022-02-22 Hoffmann La Roche Anticuerpos biespecíficos anti-hapteno/anti-receptor de la barrera hematoencefálica, complejos de los mismos y su uso como lanzaderas a través de la barrera hematoencefálica
BR112016014969A2 (pt) * 2014-01-15 2018-01-23 Hoffmann La Roche polipeptídeo, formulação farmacêutica e uso de um polipeptídeo
EP3054007A1 (en) * 2015-02-09 2016-08-10 Institut National De La Sante Et De La Recherche Medicale (Inserm) Recombinant adeno-associated virus particle purification comprising an immuno-affinity purification step
JP6959912B2 (ja) * 2015-09-23 2021-11-05 ジェネンテック， インコーポレイテッド 抗ｖｅｇｆ抗体の最適化変異体
KR20250057128A (ko) * 2015-12-30 2025-04-28 코디악 사이언시스 인코포레이티드 항체 및 이의 접합체
US12071476B2 (en) * 2018-03-02 2024-08-27 Kodiak Sciences Inc. IL-6 antibodies and fusion constructs and conjugates thereof
US20210254073A1 (en) * 2020-02-04 2021-08-19 Cornell University Methods for capture and analysis of macromolecular complexes

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119454939A (zh) * 2024-11-28 2025-02-18 北海康成(苏州)生物制药有限公司 一种欧莫扑拜单抗原液及其制备方法
CN119524125A (zh) * 2024-11-28 2025-02-28 北海康成(苏州)生物制药有限公司 一种欧莫扑拜单抗原液的生产方法及欧莫扑拜单抗原液

Also Published As

Publication number Publication date
KR20240142564A (ko) 2024-09-30
CA3251000A1 (en) 2023-08-17
WO2023154822A3 (en) 2023-09-21
IL314472A (en) 2024-09-01
WO2023154822A2 (en) 2023-08-17
MX2024009755A (es) 2024-08-20
EP4476237A2 (en) 2024-12-18
WO2023154822A8 (en) 2024-04-04
AU2023217074A1 (en) 2024-08-15
US20230250133A1 (en) 2023-08-10
JP2025505696A (ja) 2025-02-28

Similar Documents

Publication Publication Date Title
US20230250133A1 (en) Methods of purifying a product
JP7414371B2 (ja) 抗体および抗体複合体
AU2015279560B2 (en) Dual PDGF/VEGF antagonists
US9840553B2 (en) Dual PDGF/VEGF antagonists
US20240084043A1 (en) Methods of treating an eye disorder
WO2024254282A2 (en) Methods for analyzing mixed compositions of protein and protein conjugates
WO2024254281A9 (en) Compositions of conjugated and unconjugated proteins

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination